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Abstract 
The mechanism of the altered GH secretion in obesity is unclear. There is evidence that oral glucose (OG) 
administration initially decreases and subsequently stimulates GH secretion. Ghrelin is a peptide that displays 
strong growth hormone-releasing activity. Its physiological importance on GH regulation is unclear. Our aim 
was to study fasting GH concentrations and their response to OG administration in relation with ghrelin 
secretion in obese and healthy women, in order to elucidate the hypothetical participation of ghrelin on post-
oral glucose GH secretion. 36 women were included in the study. After an overnight fast, 75 g of oral glucose 
was administered; glucose, insulin, ghrelin, and PYY1–36 were obtained at baseline and during 300 min. The 
area under the curve between 0 and 300 min (AUC) of GH μ/l·min) was lower in obese patients than in 
controls; 262.5±57.5 vs. 534.9±95.6, p=0.01, for obese and controls respectively. GH peak (μg/l) was lower 
in obese patients than in controls; 3.7±0.7 vs. 7.1±1.0, p=0.012, for obese and controls, respectively. The 
AUC of total ghrelin (pg/ml·min) was lower in obese patients than in controls; 233 032±12 641 vs. 
333 697±29 877, p=0.004, for the obese patients and controls respectively. PYY1–36 was similar in obese and 
healthy women after OG. There were significant correlations between the different indices of post-oral 
glucose GH and ghrelin secretion. These data suggest that ghrelin is a physiological regulator of GH in the 
post-oral glucose state, and the decreased ghrelin secretion could be one of the mechanisms responsible for 
the altered GH secretion in obesity. 
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Introduction 
Ghrelin is a 28-amino-acid peptide, predominantly produced by the stomach, which has a 
unique structure with an n -octanoyl ester at its third serine residue, which is essential for its potent 
stimulatory activity on somatotroph secretion. It displays strong growth hormone-releasing activity 
mediated by the hypothalamus and pituitary GH secretagogue receptors [1–5]. The GH-releasing 
action of ghrelin takes place both directly on pituitary cells and through modulation of GHRH 
from the hypothalamus; some functional anti-somatostatin action has also been shown [6]. Its 
physiological importance in GH regulation is unclear. Studies to determine the effects of 
endogenous ghrelin on the control of GH secretion have yielded conflicting results. Espelund et al. 
[7], Norrelund [8], and Natalucci et al. [9] did not find a correlation between ghrelin and GH under 
fasting conditions. Avram et al. [10] did not observe any relationship with GH under fed or fasting 
conditions. Dall et al. could not find a correlation between ghrelin and GH after exercise [11] . In 
situations with increased GH secretion such as acromegaly and renal failure [12, 13] there was no 
correlation between ghrelin and GH. Muller et al. [14] showed that fasting induced a diurnal 
rhythm for total ghrelin similar to that observed in GH, but the diurnal rhythm was not present 
under fed conditions. Koutkia et al. [15] found that there is a significant regularity in cosecretion 
between ghrelin and GH in the fasted state. Misra et al. [16], found that fasting ghrelin is an 
independent predictor of basal GH secretion and GH secretory burst frequency. Nass et al. [17] 
found that under normal conditions in subjects given regular meals, endogenous acylated ghrelin 
acts to increase the amplitude of GH pulses. These inconsistent findings may be due, at least in 
part, to differences in the study design, methodology and patients studied. None of the previous 
studies have examined the relation between ghrelin and GH secretion in obesity. Data exist, which 
suggest that other gastrointestinal hormones, like PYY, could participate in GH regulation [18].  
 
In obesity there is a markedly decreased GH secretion. In both children and adults, the greater 
the body mass index (BMI), the lower the GH response to provocative stimuli, including the 
response to GH-Releasing Hormone (GHRH) [19]. The altered somatotroph function of obesity is 
not permanent; it can be reversed by a return to normal weight [20] or by short term calorie 
restriction [21]. The most striking example of secretory capacity appeared when obese subjects 
were treated with GHRH plus GH-Releasing Peptide-6 (GHRP-6) both at saturating doses, which 
resulted in a massive GH response for obese subjects [3]. This relative GH deficiency may 
contribute towards developing or maintaining the obese state [22], and GH treatment has been 
employed in obesity [23]. A meta-analysis of recombinant human GH as therapy for obesity in 
adults, suggests that GH therapy leads to a decrease in visceral adiposity and an increase in lean 
body mass, as well as beneficial changes in the lipid profile in obese adults, without inducing 
weight loss [23]. The mechanism of altered GH secretion in obesity is unclear. There is evidence 
that oral glucose (OG) administration affects GH secretion, initially decreasing GH secretion and 
subsequently stimulating GH secretion [24]. In human obesity, the oral glucose load loses its early 
inhibitory effect on GH but maintains its late stimulatory effect on somatotrope secretion. 
However, GH secretion after oral glucose was decreased in obese subjects when compared with 
the control group [25]. Circulating plasma ghrelin increases before a meal and decreases following 
the consumption of nutrients and after an oral glucose tolerance test [26–29]. Ghrelin secretion is 
altered in obesity [30, 31] and could be responsible for altered GH secretion in obesity.  
 
Our aim was to study fasting GH concentrations and their response to OG administration in 
relation to ghrelin secretion in healthy and obese women, in order to elucidate the hypothetical 
participation of ghrelin on the late postprandial GH secretion.  
  
Patients and Methods 
Patients 
We included a total of 36 women in the study (Table 1). 23 obese women, aged 39.8 ± 2.9 
years, with a BMI of 38.8 ± 1.2 kg/m
2
, were studied. As a control group, we studied 13 healthy 
women, selected from a pool of volunteers available at our unit, aged 34.4 ± 3.6 years and with a 
BMI of 22.3 ± 0.7 kg/m
2
. Both groups were homogeneous and differ only in BMI. None of the 
obese patients or controls had diabetes mellitus or other medical problems nor were they taking 
any drugs. The subjects had been eating a weight-maintaining diet for several weeks prior to the 
study. We specifically informed the patients that they should maintain their usual eating and 
exercise habits during the previous 2 weeks of the study. All the studies have been conducted in 
accordance with the Declaration of Helsinki. The study protocol was approved by our center’s 
ethical committee, and written informed consent was obtained from all patients and controls. 
Table 1. Basic characteristics of obese women and healthy control women 
 Control Woman Obese Woman P 
    
Number 13  23  
Age (years)  34.4 ± 3.6  39.8 ± 2.9  NS 
BMI (kg/m2 )  22.3 ± 0.7  38.8 ± 1.2  < 0.001 
Mid-waist circumference (cm)  79.9 ± 1.5  109.7 ± 2.6  < 0.001 
Total body fat (%)  31.4 ± 1.2  46.2 ± 0.9  < 0.001 
    
 
Values are mean ± SEM. BMI: body mass index 
Study procedure 
Between 08.30. and 09.00 AM, after an overnight fast and while seated, a peripheral venous 
line was obtained. 15 min later 75 g of oral glucose was administered. All studies were performed 
during the follicular phase of the menstrual cycle. In order to study the patients during the 
follicular phase of the menstrual cycle, all studies were done during the first 10 days from the 
beginning of the mestrual period. We obtained blood samples for glucose, insulin, GH, ghrelin, 
and PYY1–36 at baseline (fasting) and then at 30, 60, 90, 120, 150, 180, 210, 240, 270, and 300 
min. Basal levels of leptin and IGF-I were also measured. All blood samples were immediately 
centrifuged, separated and frozen at − 80° C. Samples destined to be used for the determination of 
plasma ghrelin were specifically retrieved in chilled tubes containing aprotinin and EDTA-Na, and 
then immediately centrifuged at 4° C, separated to aliquots and frozen at −80° C. Mid-waist 
circumference was measured as the midpoint between the iliac crest and the lowest rib, with the 
patient in the upright position. Measurement of the hip circumference was performed at the widest 
point, also with the subject in an upright position. Total body fat was calculated through 
bioelectrical impedance analysis (BIA), as previously described [32].  
Assays and other methods 
Serum samples were collected and stored at −80 ° C. Serum GH (μg/l) was measured by a 
solid-phase, 2-site chemiluminescent enzyme immunometric assay (Immulite, EURO / DPC) with 
a sensitivity of 0.01 μ g / l and with intra-assay coefficients of variation of 5.3%, 6.0%, and 6.5% 
for low, medium and high plasma GH levels, respectively; and with inter-assay coefficients of 
variation of 6.5%, 5.5%, and 6.6% for low, medium and high plasma GH levels respectively. IGF-
I (ng/ml) was determined by a chemiluminescence assay (Nichols Institute, San Clemente, CA, 
USA) and with intra-assay coefficients of variation of 4.8%, 5.2%, and 4.4% for low, medium and 
high plasma IGF-I levels respectively; and with inter-assay coefficients of variation of 7.7%, 
7.4%, and 4.7% for low, medium and high plasma IGF-I levels respectively. Insulin (μU/ml) was 
measured with a solid-phase 2-site chemiluminescent immunometric assay (Immulite 2000 
Insulin, DPC, Los Angeles, CA, USA) and with intra-assay coefficients of variation of 5.5%, 
3.3%, and 3.7% for low, medium and high plasma insulin levels respectively; and with inter-assay 
coefficients of variation of 7.3%, 4.1%, and 5.3% for low, medium and high plasma insulin levels 
respectively. Leptin (ng/ml) was measured by radioimmunoassay (Mediagnost, Tübingen, 
Germany) and with intra-assay and inter-assay coefficients of variation of 5.3% and 13.6%, 
respectively. Total ghrelin (pg/ml) was measured by a commercially available radioimmunoassay 
(RIA) kit (Linco Research Inc., St Charles, MO, USA), specific for total ghrelin, that uses 
125
Ilabeled ghrelin tracer and rabbit antighrelin serum with a specificity of 100%, with an intra-
assay coefficient of variation between 3.3 – 10% and an inter-assay coefficient of variation 
between 14.7 – 17.8. Plasma glucose (mg/dl) was measured with an automatic glucose oxidase 
method (Roche Diagnostics, Mannheim, Germany). All samples from a given subject were 
analyzed in the same assay run. PYY1–36 (pg/ml) was measured by a commercially available 
radioimmunoassay (RIA) kit (Linco, St Charles, MO, USA), with an intra-assay coefficient of 
variation of between 2.9 – 9.4% and an inter-assay coefficient of variation between 5.5 – 8.5%; the 
lower detection limit was 10 pg / ml. 
Statistical analysis 
The results are presented as mean values ± standard error of the mean (SEM). Fasting and post-
oral glucose biochemical and hormonal data were compared between the obese patients and 
controls. The area under the secretory curve (AUC) was used to summarize serum values at 30, 60, 
90, 120, 150, 180, 210, 240, 270, and 300 min after oral glucose. AUC was calculated with the 
trapezoidal rule (0 – 300 min), and separately for the 0 – 150 min and 150 – 300 min intervals. All 
comparisons were based on univariate, nonparametric tests. Comparisons between the patients and 
controls were based on the Mann–Whitney U test. Numerical correlations were analyzed using 
Spearman’s correlation coefficient. p-Values ≤0.05 were considered to be significant, and all tests 
were considered as being 2-sided. For graphic presentation we use mean values ± SEM. SPSS 17.0 
software (Chicago, IL, USA) was used to produce the statistical analysis.  
Results 
The basic characteristics of the healthy control group and patients are shown in Table 1. 
Fasting serum levels 
The fasting serum levels are presented in Table 2. Fasting glucose (mg/dl, mean ± SEM) levels 
were higher in obese women than in healthy control women; 98.4 ± 2.0 vs. 86.5 ± 3.0, p = 007, for 
the obese patients and controls respectively. Fasting insulin (μU/ml, mean ± SEM) levels were 
higher in obese women than in healthy control women; 17.7 ± 6.9 vs. 4.0 ± 0.8, p = 0.0001, for the 
obese patients and controls respectively. Fasting GH (μg/l, mean ± SEM) levels were similar in 
obese women and in healthy control women; 1.2 ± 0.4 vs. 1.6 ± 0.8, p = NS, for the obese patients 
and controls respectively. Fasting total ghrelin (pg/ml, mean ± SEM) levels were lower in obese 
women than in healthy control women; 898 ± 66 vs. 1 376 ± 163, p = 0.01, for the obese patients 
and controls respectively. Fasting IGF-I (ng/ml, mean ± SEM) levels were lower in obese women 
than in healthy control women; 107.0 ± 10.6 vs. 161.0 ± 11.2, p = 0.001, for the obese patients and 
controls respectively. Fasting leptin (ng/ml, mean ± SEM) levels were higher in obese women than 
in healthy control women, 65.5 ± 5.5 vs. 21.3 ± 2.6, p = 0.0001, for obese patients and controls 
respectively. Fasting PYY1–36 (pg/ml, mean ± SEM) levels were similar in our group of otherwise 
healthy obese women and control women; 135.4 ± 9.7 vs. 133.2 ± 13.3, p = NS, for the obese 
patients and controls respectively. 
Table 2. Fasting and after oral glucose biochemical and hormonal data in obese women and healthy control women 
 Control Woman Obese Woman p 
    
Fasting glucose (mg/dl)  86.5 ± 3.0  98.4 ± 2.0  0.007 
Fasting insulin (μUI/ml) 4.0 ± 0.8  17.7 ± 6.9  < 0.001 
Fasting triglycerides (mg/dl) 72.5 ± 3.8  118.1 ± 6.4  0.006 
Fasting GH (μg/l) 1.6 ± 0.8  1.2 ± 0.4  NS 
Fasting IGF-I (ng/ml)  161.0 ± 11.2  107.0 ± 10.6  0.001 
Fasting leptin (ng/ml)  21.3 ± 2.6  65.5 ± 5.5  < 0.001 
Fasting total ghrelin (pg/ml) 1 376.1 ± 162.9  898.3 ± 65.7  0.01 
Fasting PYY1–36 (pg/ml)  133.2 ± 13.3  135.4 ± 9.7  NS 
Peak glucose (mg/dl)  138.5 ± 7.4  170.4 ± 8.7  0.022 
AUC0–300 glucose (mg/dl min)  26 925.0 ± 1 245.7  31 469.3 ± 803.8  0.005 
AUC0–150 glucose (mg/dl min)  15 598.8 ± 886.4  19 342.2 ± 797.8  0.01 
AUC150–300 glucose (mg/dl min) 11 326.1 ± 440.8  12 127.2 ± 272.6  NS 
Peak insulin (μUI/ml)  50.0 ± 6.1  115.7 ± 14.0  < 0.001 
AUC0–300 insulin (μUI/ml min)  5 705.3 ± 537.8  12 561.4 ± 1 029.6  < 0.001 
AUC0–150 insulin (μUI/ml min)  4 629.5 ± 497.5  9 778.0 ± 973.3  < 0.001 
AUC150–300 insulin (μUI/ml min) 1 075.8 ± 112.3  2 783.4 ± 240.5  < 0.001 
Peak GH (μg/l)  8.6 ± 1.1  3.5 ± 0.8 < 0.001 
AUC0–300 GH (μg/l min)  652.1 ± 116.0  265.0 ± 64.1  0.001 
AUC0–150 GH (μg/l min) 142.0 ± 51.5  71.4 ± 23.1  NS 
AUC150–300 GH (μg/l min)  510.1 ± 89.0  193.6 ± 50.7  < 0.001 
Nadir total ghrelin (pg/ml)  940.8 ± 93.8  667.5 ± 41.4  0.022 
AUC0–300 total ghrelin (pg/ml min)  362 687 ± 39 430  243 128 ± 14 867  0.01 
AUC0–150 total ghrelin (pg/ml min)  157 590 ± 15 772  113 673 ± 6 865  0.026 
AUC150–300 total ghrelin (pg/ml min)  205 097 ± 23 740  129 454 ± 8 230  0.005 
Peak PYY1– 36 (pg/ml)  143.5 ± 16.1  162.0 ± 10.2  NS 
AUC0–300 PYY1–36 (pg/ml min)  34 923.5 ± 3 441.3  36 937.8 ± 2 146.4  NS 
AUC0–150 PYY1–36 (pg/ml min)  19 509.2 ± 2 071.8  20 237.6 ± 1 254.5  NS 
AUC150–300 PYY1–36 (pg/ml min)  15 414.2 ± 1 432.9  16 700.2 ± 946.3  NS 
    
 
Values are mean ± SEM. AUC0–300 : area under the secretory curve between time 0–300 min. AUC0–150 : area under the 
secretory curve between time 0– 150 min. AUC150–300 : area under the secretory curve between time 150 – 300 min 
Serum levels after oral glucose 
The post-oral glucose serum levels are presented in Table 2. Glucose was higher in obese 
women than in healthy control women after the 300-min OG (Fig. 1a). The AUC of glucose 
(mg/dl min, mean ± SEM) between 0 and 300 min was higher in obese patients than in controls; 
31 169 ± 660 vs. 28 239 ± 1 176, p = 0.016, for the obese patients and controls respectively. Peak 
glucose (mean ± SEM) levels were higher in our group of otherwise healthy obese women and 
controls; 170.4 ± 8.7 vs. 138.5 ± 7.4, p = 0.022, for the obese patients and controls respectively. 
Insulin was higher in obese women than in healthy control women after the 300 min OG (Fig. 1b). 
The AUC of insulin (μU/ml min, mean ± SEM) between 0 and 300 min was higher in the obese 
patients than in controls; 12 616 ± 867 vs. 5 845 ± 605, p = 0.0001, for obese patients and controls 
respectively. Peak insulin (μU/ml, mean ± SEM) levels were higher in the obese patients than in 
the control subjects; 115.7 ± 14.0 vs. 50.0 ± 6.1, p = 0.0001, for the obese patients and controls 
respectively. GH was lower in the obese women than in the healthy control women after OG (Fig. 
2a). The AUC of GH (μg/l min, mean ± SEM) between 0 and 300 min was lower in the obese 
patients than in the controls; 262.5 ± 57.5 vs. 534.9 ± 95.6, p = 0.01, for the obese patients and 
controls respectively. Peak GH (μg/l, mean ± SEM) levels were lower in obese patients than in 
control subjects, 3.7 ± 0.7 vs. 7.1 ± 1.0, p = 0.012, for obese patients and controls respectively. 
Total ghrelin was lower in obese women than in healthy control women after OG (Fig. 2b). The 
AUC of total ghrelin (pg/ml min, mean ± SEM) between 0 and 300 min was lower in obese 
patients than in controls; 233 032 ± 12 641 vs. 333 697 ± 29 877, p = 0.004, for the obese patients 
and controls respectively. Nadir total ghrelin (pg/ml, mean ± SEM) levels were lower in obese 
women than in controls; 667.5 ± 41.4 vs. 940.8 ± 93.8, p = 0.022, for the obese patients and 
controls respectively. PYY1–36 was similar in obese women and healthy control women after the 
300 min OG (Fig. 3). The AUC of PYY1–36 (pg/ml min, mean ± SEM) between 0 and 300 min was 
similar in obese women and healthy control women; 36 938 ± 2 146 vs. 34 923 ± 3 441, p = NS, 
for the obese patients and controls respectively. Peak PYY1–36 (pg/ml, mean ± SEM) levels were 
similar in obese women and healthy control women; 162 ± 10 vs. 144 ± 16, p = NS, for the obese 
patients and controls respectively.  
 
 
 
   
Fig. 1a: Mean ± SEM plasma glucose (mg/dl) in controls 
and obese women during the prolonged oral glucose 
tolerance test. *p<0.05 and **p<0.01 between controls 
and obese women at that time point. 
b: Mean ± SEM plasma insulin levels (μU/ml) in controls 
and obese women during the prolonged oral glucose 
tolerance test. *p< 0.05 and **p<0.01 between controls 
and obese women at that time point. 
 Fig. 2a: Mean ± SEM plasma GH levels (μg/l) in controls 
and obese women during the prolonged oral glucose 
tolerance test. *p<0.05 and **p< 0.01 between controls 
and obese women at that time point. 
b: Mean ± SEM plasma total ghrelin levels (pg/ml) in 
controls and obese women during the prolongued oral 
glucose tolerance test. *p<0.05 and **p< 0.01 between 
controls and obese women at that time point. 
 
   
   
Fig. 3 Mean ± SEM plasma PYY1–36 levels (pg/ml) in controls 
and obese women during the prolonged oral glucose tolerance 
test. The differences were nonstatistically significant between 
controls and obese women at any time point. 
  
 
Correlations 
We analyzed if there was any significant correlation between the GH secretion indices and 
ghrelin secretion indices in the entire group of obese women and healthy control women. There 
were signifi cant correlations between the different indices of GH secretion and ghrelin secretion 
(Table 3), suggesting that higher ghrelin values are associated with higher GH secretion values. 
These correlations persisted after adjusting for age, BMI and other obesity indices, glucose and 
insulin in a multiple regression analysis.  
Table 3. Correlations between GH (Peak: μg/l and AUC: μg/l min) and ghrelin (Nadir: pg/ml and AUC: pg/ml  min) 
secretion in the entire group of normal and obese women 
 GH Peak  AUC0-300H  AUC150-300GH 
 r p  r p  r p 
         
Nadir total ghrelin 0.353 0.035  0.365 0.029  0.266 0.117 
AUC0–300 total ghrelin  0.419 0.011  0.425 0.010  0.330 0.049 
AUC0–150 total ghrelin  0.394 0.017  0.425 0.014  0.305 0.07 
AUC150–300 total ghrelin  0.442 0.007  0.447 0.006  0.373 0.025 
         
 
AUC0–300 : area under the secretory curve between time 0–300 min. AUC0–150 : area under the secretory curve between time 
0–150 min. 
AUC150–300 : area under the secretory curve between time 150–300 min 
Discussion 
We have found that after OG in healthy and obese women there is a significant correlation 
between the AUC of ghrelin and the AUC of GH. After OG, initial GH secretion, between 0 – 150 
min, is similarly suppressed in normal and obese patients, but the late response, between 150 – 300 
min, is decreased in obese patients. These data show that ghrelin secretion after OG is probably an 
important regulator of late GH secretion, between 150 – 300 min, after OG in women and that the 
decreased GH secretion of obesity after an OG is probably due to the altered ghrelin secretion 
found in obese patients.   
Ghrelin is a natural ligand for GHS-R and potently stimulates GH release when administered 
exogenously. Although ghrelin is more than a natural GHS, the best established action of 
exogenously administered ghrelin is its potent stimulation of pituitary GH secretion [1, 4, 28, 33]. 
The GH-releasing action of ghrelin takes place both at pituitary and hypothalamic level [6, 34]. 
Human studies with orally active long-acting GH secretagogues, which act through the GHS-R 
[35] have shown an increase in GH secretion. Animal studies by Zizzari et al. [36] using a GHS-R 
antagonist support the results that endogenous acylated ghrelin modifies circulating GH release 
during the fed state. Both sc and intracerebroventricular infusion in the rat with the GHS-R 
antagonist BIM-28163 lowered the GH pulse amplitude. In humans a GHS-R missense mutation, 
which impairs the constitutive activity of the GHS-R, is associated with short stature [37]. 
Consistent with these results, GHS-R-null mice have lower IGF-I levels when compared with 
wild-type animals [38]. These data implies that endogenous ghrelin plays a role in GH regulation. 
Several studies have investigated the relationship between ghrelin and GH secretion. Espelund et 
al. [7], Norrelund [8] and Natalucci et al. [9] did not find a correlation between ghrelin and GH 
under fasting conditions. Avram et al. [10] used an acylated ghrelin RIA, but did not observe any 
relationship with GH under fed or fasting conditions. Their differing results may be connected 
with protocol differences, and also their study population included both men and women. Dall et 
al. could not find a correlation between ghrelin and GH after exercise [11]. Our previous findings 
in pathophysiological situations with increased GH secretion such as acromegaly and renal failure 
[12, 13] could not find a correlation between ghrelin and GH. Muller et al. [14] showed that 
fasting induced a diurnal rhythm for total ghrelin similar to that observed in GH levels, but the 
diurnal rhythm was not present when subjects were tested under fed conditions. Koutkia et al. [15] 
used cross-approximate entropy analysis and found that there is a significant regularity in 
cosecretion between ghrelin and GH in the fasted state; however, this was only found during the 
night. Misra et al. [16], using deconvolution analysis for GH and total ghrelin in healthy 
adolescents and adolescents with anorexia, found that fasting ghrelin is an independent predictor 
of basal GH secretion and GH secretory burst frequency. Blood samples were measured overnight 
for 12 h (20:00 – 08:00 h) every 30 min. In studies carried out on 8 healthy young men, Nass et al. 
[17] found a significant relationship between GH secretion peak amplitudes and mean circulating 
acylated ghrelin levels during the fed condition. In agreement with our results in healthy and obese 
women they conclude that under normal conditions in subjects given regular meals, endogenous 
ghrelin acts to increase the amplitude of GH pulses. On the other hand, the study by Zizzari et al. 
[36] using a GHS-R antagonist favors a direct modulatory role of circulating ghrelin on GH 
release as do studies with ghrelin mimetics [35]. Recent studies in mice without the Ghrelin O -
acyltransferase (GOAT) gene have found that an essential function of ghrelin in mice is elevation 
of GH levels during severe calorie restriction, thereby preserving blood glucose and preventing 
death [39] . Our findings are in line with previous studies, which suggest that the inhibitory and 
stimulatory effects of glucose load on GH secretion are unlikely to be due to direct biphasic 
modulation of hypothalamic somatostatin [25] or GHRH release, as exogenous GHRH increases 
GH secretion after oral glucose administration [25]. As shown in Fig. 2 there is a relatively greater 
decline in GH in obese compared with healthy subjects, despite a smaller relative decline in 
ghrelin levels following glucose loading, that response could be due to the altered free fatty acids 
of obesity, as GH response to ghrelin is partially refractory to the inhibitory effect of free fatty 
acids [40] . We have previously shown that the decreased GH secretion of obesity is at least in part 
due to the increased free fatty acids present in that disease [41]. Based on our data, we cannot 
exclude the possibility that there is a negative feedback loop between GH and circulating ghrelin 
levels. However, the current literature on this subject is controversial [42], and our findings, 
together with those of other researchers, do not support the existence of any such negative 
feedback loop [13, 17, 43]. The relationship between ghrelin, which increases food intake, and GH 
found during the late fed state would be beneficial to man because the anabolic changes induced 
by GH require the presence of adequate nutrition [7, 17].  
  
Because our study was not interventional and the analysis is based on correlation, we cannot 
exclude the existence of one common or several separate factors that control both GH release and 
circulating ghrelin levels simultaneously. For example, insulin inhibits GH secretion and has a 
direct transcriptional inhibitory regulation of the GH gene [44, 45]. Insulin rises after OG and has 
been suggested to decrease circulating ghrelin levels [46, 47]. Therefore, a possible role for insulin 
as a common regulator of circulating ghrelin and GH after OG cannot be excluded, even though 
the correlation between GH and ghrelin persisted after adjusting for insulin. During mid-puberty, 
at a time when GH levels are the highest, PYY is at a nadir, and log nadir GH correlated inversely 
with log PYY [18]. These associations remained significant even after controlling for BMI, 
suggesting that PYY could have a role in the nutritional regulation of GH secretion. This is why 
we also measured PYY, and could not find any correlation between GH and PYY secretion. 
Another concern regarding our study is that we did not measure acylated ghrelin. Although 
acylated ghrelin has proved to be the biologically active form in the control of GH secretion, most 
of the leading studies on the correlation between GH and ghrelin secretion have focused on the 
estimation of total ghrelin [7 – 9, 11, 14 – 16], and there are concerns regarding the especificity of 
available acyl-ghrelin assays [48] and more important the stability of plasma acylated ghrelin once 
collected. Recent studies have evaluated the different methods for the stabilization of acylghrelin 
in human blood collections, in order to improve its stability [49]. The primary cause of impaired 
GH secretion in obesity could be an altered hypothalamus, abnormal pituitary function, or a 
perturbation of the peripheral signals acting at either the pituitary or hypothalamic level. Different 
studies suggest that the pathophysiological mechanism responsible for GH hyposecretion in 
obesity is multifactorial, and there is probably a chronic state of somatostatin hypersecretion, 
increased FFA and decreased ghrelin [4, 41, 50, 51]. The findings of the present study where we 
have found that after OG in obese women there is a significant correlation between ghelin and GH 
secretion, suggest that the decreased ghrelin secretion in obesity is one of the mechanisms 
responsible for altered GH secretion in obesity. The decreased stimulation of GH release in obese 
subjects after OG may promote the retention of fat mass. However, studies have demonstrated that 
apparently all the defects in the GH IGF-I axis in obesity are reversible with diet-induced and 
surgical-induced large weight loss [20, 52 – 54]. The recovery of the GH IGF-I axis after weight 
loss suggests an acquired defect, rather than a preexisting disorder. However, the impaired GH 
IGF-I axis may intervene in the expansion and maintenance of fat mass, and contribute to 
perpetuation of the obese state. In conclusion, the data presented suggest that ghrelin is a 
physiological regulator of GH in the postprandial state, and that the decreased ghrelin secretion in 
obesity could be one of the mechanisms responsible for the altered GH secretion in obesity.  
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